Daily Sepsis Research Analysis
Analyzed 34 papers and selected 3 impactful papers.
Summary
Three mechanistic and translational sepsis studies stood out today: chemogenetic CasRx RNA editing delivered to macrophages attenuated inflammation in murine sepsis; a microbiome-derived metabolite, hippuric acid, amplified macrophage inflammation via TLR-MyD88 and cholesterol remodeling with levels linked to sepsis mortality; and a newly defined MafG/Bach1–Lcn2 axis drove ferroptosis in sepsis-induced acute lung injury, with genetic knockdown improving survival and a small-molecule lead (AB4) showing efficacy.
Research Themes
- Macrophage-targeted immunomodulation and RNA editing therapeutics
- Microbiome-derived metabolites shaping innate immunity and lipid/cholesterol remodeling in sepsis
- Ferroptosis and redox homeostasis as drivers of sepsis-induced organ injury
Selected Articles
1. In vivo chemogenetic RNA editing of macrophages by bioengineered viruses for sepsis treatment.
The authors engineered biomineralized lentiviral vectors carrying CasRx RNA-editing machinery and chemogenetic switches to target M1 macrophages in sepsis. Ligand-triggered activation repeatedly downregulated NLRP3 mRNA in vivo, attenuating inflammatory responses and demonstrating efficacy across mouse sepsis models.
Impact: Introduces a controllable, macrophage-targeted RNA-editing therapy for sepsis, a paradigm shift toward programmable immunomodulation. Demonstrates in vivo efficacy and repeatability, opening a translational path for RNA therapeutics in critical illness.
Clinical Implications: While early-stage, this approach suggests a future avenue for precise immunomodulation in septic patients by transiently silencing inflammasome drivers (e.g., NLRP3). It provides a blueprint for macrophage-targeted gene therapies but requires substantial safety validation before clinical use.
Key Findings
- Developed biomineralized lentiviral vectors with chemogenetic switches to activate CasRx RNA editing selectively in M1 macrophages.
- Ligand-induced activation enabled precise and repeated downregulation of NLRP3 mRNA in vivo.
- Demonstrated attenuation of inflammatory responses and therapeutic efficacy across murine sepsis models.
Methodological Strengths
- In vivo chemogenetic control enabling on-demand and repeatable RNA editing.
- Targeted delivery to pathogenic M1 macrophage populations with demonstrated efficacy in multiple murine models.
Limitations
- Preclinical animal study with no human safety or efficacy data.
- Potential safety concerns related to viral delivery, immunogenicity, and off-target RNA editing remain to be addressed.
Future Directions: Evaluate safety, biodistribution, and durability in large-animal models; expand targets beyond NLRP3; and develop non-viral or transient delivery platforms to facilitate clinical translation.
Sepsis, a life-threatening condition arising from a dysregulated host response to infection, remains a significant clinical challenge with limited therapeutic options. RNA editing presents a promising avenue for modulating gene expression to attenuate the inflammatory cascade characteristic of sepsis. Here, we introduce an approach utilizing chemogenetic activation of CasRx-based RNA editing via bioengineered lentiviruses for the treatment of sepsis. Our strategy involves the targeted delivery of biomineralized len
2. Aromatic microbial metabolite hippuric acid enhances inflammatory responses in macrophages via TLR-MyD88 signaling and lipid remodeling.
Hippuric acid, a microbe-derived aromatic metabolite, amplified MyD88-dependent TLR signaling and pro-inflammatory responses in macrophages, increased cholesterol biosynthesis/lipid accumulation, and worsened survival in E. coli-infected mice. Human macrophages showed similar potentiation, and elevated hippuric acid correlated with sepsis mortality.
Impact: Links a specific microbiome metabolite to innate immune amplification via a defined pathway and lipid remodeling, bridging metabolomics with sepsis outcomes. Identifies potential biomarker and therapeutic axes (MyD88 signaling and cholesterol metabolism).
Clinical Implications: Hippuric acid may serve as a risk stratification biomarker in sepsis and highlights therapeutic strategies targeting MyD88-TLR signaling or cholesterol biosynthesis to temper hyperinflammation; microbiome modulation could also be explored.
Key Findings
- Hippuric acid enhanced macrophage responses to MyD88-dependent TLR ligands but not TRIF, STING, or NOD2 stimuli; MyD88 deletion abrogated effects.
- Induced cholesterol biosynthesis and lipid accumulation; lowering cellular cholesterol blunted pro-inflammatory potentiation.
- In E. coli-infected mice, hippuric acid increased inflammation, activated innate immune cells, and reduced survival.
- Elevated hippuric acid levels potentiated pro-inflammatory responses in human macrophages and correlated with sepsis mortality.
Methodological Strengths
- Integrated untargeted metabolomics with transcriptomics and lipidomics to identify mechanism.
- Genetic validation via MyD88 knockout and cross-species confirmation in human macrophages and murine models.
Limitations
- Human data are correlational (mortality association) without causal intervention.
- Dosing and exposure in animal models may not mirror physiological concentrations in patients.
Future Directions: Prospective clinical studies to validate hippuric acid as a biomarker; interventional studies targeting MyD88 signaling or cholesterol biosynthesis; and microbiome manipulation to modulate hippuric acid levels.
The gut microbiome produces diverse metabolites shaping immunity, yet their pro-inflammatory potential remains unclear. Using untargeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) metabolomics, we identified hippuric acid-an aromatic, microbe-derived metabolite-as a potent enhancer of inflammatory responses during Escherichia coli infection. Hippuric acid administration heightened inflammation, activated innate immune cells, and reduced survival in infected mice. In vitro, hippuric a
3. The MafG/Bach1-Lcn2 transcriptional axis drives ferroptosis in Sepsis-induced Acute Lung Injury via disrupting redox homeostasis.
MafG was upregulated in septic lungs and, together with Bach1, directly activated Lcn2 transcription, driving iron accumulation, lipid peroxidation, and ferroptosis in alveolar epithelium. AAV-mediated MafG knockdown mitigated lung injury, restored redox balance, improved survival, and Anemoside B4 emerged as a potential MafG inhibitor with in vivo protective effects.
Impact: Defines a novel transcriptional pathway (MafG/Bach1–Lcn2) linking oxidative stress to ferroptosis in septic lung injury and demonstrates survival benefit via genetic intervention, nominating AB4 as a lead compound.
Clinical Implications: Identifies actionable nodes (MafG/Bach1 and Lcn2) for anti-ferroptosis therapy in sepsis-induced lung injury; supports development of small-molecule MafG inhibitors (e.g., AB4) and gene-silencing strategies.
Key Findings
- MafG is upregulated in septic lungs and exacerbates ferroptosis; knockdown is protective.
- MafG forms a functional heterodimer with Bach1 to directly activate Lcn2 transcription, driving iron accumulation and lipid peroxidation.
- AAV-shMafG reduced lung injury, improved redox balance, and enhanced survival in CLP mice.
- Anemoside B4 binds MafG in biophysical assays and confers in vivo protection as a potential MafG inhibitor.
Methodological Strengths
- Comprehensive mechanistic validation (co-IP, mass spectrometry, luciferase reporter) linking transcriptional control to ferroptosis.
- In vivo efficacy with AAV-mediated knockdown and survival endpoints; orthogonal validation of small-molecule binding (docking, SPR).
Limitations
- Preclinical models without human tissue validation or clinical data.
- Specificity and pharmacokinetics of AB4 require further characterization; translational dosing remains uncertain.
Future Directions: Validate MafG/Bach1–Lcn2 signaling in human SALI samples; optimize and profile AB4 analogs; assess combination strategies with ferroptosis inhibitors and anti-inflammatory agents.
BACKGROUND AND OBJECTIVE: Sepsis-induced acute lung injury (SALI) is a life-threatening condition with high mortality, intimately linked to the disruption of intracellular redox homeostasis. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has been implicated in sepsis-related organ dysfunction. However, its upstream transcriptional regulators, particularly within alveolar epithelial cells, remain poorly defined. This study aims to investigate the role of